Sinovac Biotech announced that its board of directors unanimously determined that the partial tender offer by Alternative Liquidity to acquire up to 10M common shares of Sinovac for 3c per share in cash is not advisable and is not in the best interests of the company or its shareholders. Accordingly, the board of directors recommends that the Shareholders reject the tender offer and not tender their Shares for purchase pursuant to the offer to purchase by Alternative Liquidity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
